Acorda Strikes Patent Deal To Delay Par's Generic Ampyra
Acorda Therapeutics Inc. said Wednesday it has ended its Delaware federal court suit accusing Par Pharmaceutical Inc. of flouting four patents covering the multiple sclerosis drug Ampyra after the companies agreed...To view the full article, register now.
Already a subscriber? Click here to view full article